The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice.
With a frequency of 2.2 cases per 100,000 population in Russia, Hodgkin's lymphoma (HL) is one of the most common malignant neoplasms in young people. In connection with the predominant spread of HL among young people, the issue of effective treatment of various forms of HL remains relevant. Cu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ANO "Perspective of oncology"
2021-06-01
|
| Series: | Южно-Российский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.cancersp.com/jour/article/view/99 |
| _version_ | 1826573036878299136 |
|---|---|
| author | I. A. Kamaeva I. B. Lysenko N. V. Nikolaeva T. F. Pushkareva E. A. Kapuza Ya. S. Gaisultanova A. V. Velichko |
| author_facet | I. A. Kamaeva I. B. Lysenko N. V. Nikolaeva T. F. Pushkareva E. A. Kapuza Ya. S. Gaisultanova A. V. Velichko |
| author_sort | I. A. Kamaeva |
| collection | DOAJ |
| description | With a frequency of 2.2 cases per 100,000 population in Russia, Hodgkin's lymphoma (HL) is one of the most common malignant neoplasms in young people. In connection with the predominant spread of HL among young people, the issue of effective treatment of various forms of HL remains relevant. Currently, 70-90 % of patients with HL who have received standard chemotherapy or chemoradiotherapy have a long period of remission. However, 10 % of patients with progressive course, can`t achieve a response, and 30 % of patients subsequently recur. The standard approach of treating recurrent and/or refractory HL after initial treatment is “salvage therapy” followed by consolidation with high-dose chemotherapy and stem cell transplantation. Although there is a model for treating these patients, recent research has focused on improving the effectiveness and tolerability of rescue therapy. The use of anti- PD-1 drugs opens up new possibilities for the treatment of recurrent/refractory HL. The article describes the results of using checkpoint inhibitors for patients with a history of multi- course chemotherapy. Inhibitors of immune check points were supplemented in the 3rd and subsequent lines of ChT. A clinical case with immunotherapy supplementation in a patient with severe comorbidity is also presented. |
| first_indexed | 2024-04-10T03:42:26Z |
| format | Article |
| id | doaj.art-3856a8baee1a49c48b9e28bd6708cbf0 |
| institution | Directory Open Access Journal |
| issn | 2686-9039 |
| language | Russian |
| last_indexed | 2025-03-14T12:36:32Z |
| publishDate | 2021-06-01 |
| publisher | ANO "Perspective of oncology" |
| record_format | Article |
| series | Южно-Российский онкологический журнал |
| spelling | doaj.art-3856a8baee1a49c48b9e28bd6708cbf02025-03-02T09:21:50ZrusANO "Perspective of oncology"Южно-Российский онкологический журнал2686-90392021-06-0122344110.37748/2686-9039-2021-2-2-439The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice.I. A. Kamaeva0I. B. Lysenko1N. V. Nikolaeva2T. F. Pushkareva3E. A. Kapuza4Ya. S. Gaisultanova5A. V. Velichko6National Medical Research Centre for Oncology of the Ministry of Health of RussiaNational Medical Research Centre for Oncology of the Ministry of Health of RussiaNational Medical Research Centre for Oncology of the Ministry of Health of RussiaNational Medical Research Centre for Oncology of the Ministry of Health of RussiaNational Medical Research Centre for Oncology of the Ministry of Health of RussiaNational Medical Research Centre for Oncology of the Ministry of Health of RussiaФГБУ «НМИЦ онкологии» Минздрава РоссииWith a frequency of 2.2 cases per 100,000 population in Russia, Hodgkin's lymphoma (HL) is one of the most common malignant neoplasms in young people. In connection with the predominant spread of HL among young people, the issue of effective treatment of various forms of HL remains relevant. Currently, 70-90 % of patients with HL who have received standard chemotherapy or chemoradiotherapy have a long period of remission. However, 10 % of patients with progressive course, can`t achieve a response, and 30 % of patients subsequently recur. The standard approach of treating recurrent and/or refractory HL after initial treatment is “salvage therapy” followed by consolidation with high-dose chemotherapy and stem cell transplantation. Although there is a model for treating these patients, recent research has focused on improving the effectiveness and tolerability of rescue therapy. The use of anti- PD-1 drugs opens up new possibilities for the treatment of recurrent/refractory HL. The article describes the results of using checkpoint inhibitors for patients with a history of multi- course chemotherapy. Inhibitors of immune check points were supplemented in the 3rd and subsequent lines of ChT. A clinical case with immunotherapy supplementation in a patient with severe comorbidity is also presented.https://www.cancersp.com/jour/article/view/99hodgkin lymphomaimmunotherapyrefractoryrelapsetargeted therapyclinical experience |
| spellingShingle | I. A. Kamaeva I. B. Lysenko N. V. Nikolaeva T. F. Pushkareva E. A. Kapuza Ya. S. Gaisultanova A. V. Velichko The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice. Южно-Российский онкологический журнал hodgkin lymphoma immunotherapy refractory relapse targeted therapy clinical experience |
| title | The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice. |
| title_full | The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice. |
| title_fullStr | The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice. |
| title_full_unstemmed | The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice. |
| title_short | The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice. |
| title_sort | use of immunotherapy for the treatment of refractory forms of hodgkin lymphoma in real clinical practice |
| topic | hodgkin lymphoma immunotherapy refractory relapse targeted therapy clinical experience |
| url | https://www.cancersp.com/jour/article/view/99 |
| work_keys_str_mv | AT iakamaeva theuseofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT iblysenko theuseofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT nvnikolaeva theuseofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT tfpushkareva theuseofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT eakapuza theuseofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT yasgaisultanova theuseofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT avvelichko theuseofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT iakamaeva useofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT iblysenko useofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT nvnikolaeva useofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT tfpushkareva useofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT eakapuza useofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT yasgaisultanova useofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice AT avvelichko useofimmunotherapyforthetreatmentofrefractoryformsofhodgkinlymphomainrealclinicalpractice |